Ignite Creation Date:
2024-05-05 @ 5:06 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00386061
Status:
COMPLETED
Last Update Posted:
2009-04-20
First Post:
2006-10-10
Brief Title:
Rimonabant in Obesity Over a 2-Year Duration RIO-Europe
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Parallel-Group Fixed-Dose Multicenter Study of Weight-Reducing Effect and Safety of SR141716 in Obese Patients With or Without Comorbidities RIO-Europe
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective was to assess the effect of SR141716 on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with or without comorbidities
The main secondary objectives were to assess the effect of SR141716 on lipid parameters HDL-C TG glucose tolerance status the rate of patients with metabolic syndrome waist circumference glycemic parameters
The main secondary objectives were to assess the effect of SR141716 on lipid parameters HDL-C TG glucose tolerance status the rate of patients with metabolic syndrome waist circumference glycemic parameters
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None